Jefferies reiterates Alcon stock Buy rating, lowers estimates

Alcon reported Q3 2026 sales of $2.717B, up 5% YoY. Net sales for the first nine months rose 7% to $8.2B. EPS declined 40% due to impairments and efficiency costs. The company highlighted product innovations, acquisitions, and narrowed its 2026 outlook.

Alcon reported Q3 2026 net sales of $2.7B, up 5% YoY, with Vision Care and Surgical segments growing. Contact lens sales reached $737M, up 4%, driven by premium products. Surgical segment saw 4% growth, but implantables declined 2%. The company tightened full-year guidance, expecting 6% sales growth at constant currency. Operating income increased to $381M in Q3, with margin expanding to 14%.

Alcon Inc (ALC) reported Q3 2026 sales growth but faced challenges in implantable sales and competitive pressures. The company narrowed its 2026 core operating margin expansion guidance to 100-150 basis points and core EPS growth to 12-14%. Alcon expects 2027 headwinds from lapping 2026 rollouts, tariff refunds, and inflation. The Neurotech acquisition is anticipated to be a near-term margin headwind.

Alcon (ALC) shares dropped 4% after reporting a 2% decline in implantables sales due to U.S. competition and narrowing its 2026 outlook. Q3 net sales rose 5% to $2.7B, with surgical and vision care segments growing, while implantables fell to $422M. The company now expects core EPS growth of 12-14% and net sales growth of about 6%.

Alcon AG stock fell 5.6% to CHF 58.42 after mixed Q3 2026 results. Revenue of $2.72B missed forecasts, growing 4.2% YoY, down from 7% in H1. Implantable lens sales declined due to U.S. competition. Management lowered full-year EPS growth guidance to 12–14% and market growth to ~3%. CEO cited new product launches and acquisitions as positives, but guidance cuts drove the sell-off.

Alcon shares dropped 6% after the company lowered its market growth outlook to 3% for 2026, down from 3-4%. It also reduced its annual earnings growth forecast to 12-14%. Q3 sales rose 5% to $2.72B, missing expectations, with implantable sales falling 2%. Analysts noted profit growth concerns, citing a sluggish US cataract market and competition.